


Exclusively **inclusive**



Annual Report 2015





Exclusively **inclusive**

At Biocon, we are driven by a vision to develop specialty biopharmaceuticals that address the global need for effective, safe and affordable biologics.

We have made consistent and significant investments in research to strengthen our exclusive positioning.

Our commitment to be inclusive in our reach is reflected in our patient-centric approach towards providing affordable medicines for chronic diseases to billions across the world.

This 'exclusive and inclusive' combination has reinforced our relevance as a sensitive corporate citizen engaged in a humanitarian business with a focus on creating value for diverse stakeholders. E X C L U S I V E L Y I N C L U S I V E

Our 'Exclusively inclusive' approach is aimed at making a difference to global health.

Biocon is developing novel biologics and biosimilars for addressing chronic diseases like cancer, diabetes and autoimmune conditions for patients across the globe. $\mathsf{E} \mathsf{X} \mathsf{C} \mathsf{L} \mathsf{U} \mathsf{S} \mathsf{I} \mathsf{V} \mathsf{E} \mathsf{L} \mathsf{Y} \quad \textbf{I} \textbf{N} \textbf{C} \textbf{L} \textbf{U} \textbf{S} \textbf{I} \textbf{V} \textbf{E}$

We believe our biotechnology business is a humanitarian engagement.

Our BIOMAb EGFR[®], a novel biologic, has benefited thousands of patients as an affordable therapy for head and neck cancer.

CANMAb[™], introduced in 2014 as the world's first affordable follow-on Trastuzumab for HER2-positive metastatic breast cancer, is making a significant impact.

E X C L U S I V E L Y I N C L U S I V E

We are driven by our passion to develop pharmaceuticals which can potentially benefit a billion patients.

As Asia's largest insulins producer, we are making a difference to diabetic patients the world over with our most affordable rh-Insulin and Insulin Glargine. Biocon's Insugen[®] is the largest generic insulin brand in India. For decades, our global scale in statins has benefited millions of patients. Our commercial footprint extends to over 100 countries.

$\mathsf{E} \mathsf{X} \mathsf{C} \mathsf{L} \mathsf{U} \mathsf{S} \mathsf{I} \mathsf{V} \mathsf{E} \mathsf{L} \mathsf{Y} \quad \textbf{I} \textbf{N} \textbf{C} \textbf{L} \textbf{U} \textbf{S} \mathsf{I} \textbf{V} \textbf{E}$

Biocon: Reconciling an exclusive business model with an inclusive social commitment.

Our efforts are targeted at affordable innovation that enables us to develop complex biopharmaceuticals at lower costs, thereby benefiting larger patient pools.

Our Oral Insulin under development has the potential to transform diabetes management the world over.

Our Itolizumab is a 'first-in-class' novel biologic that aims to change the treatment paradigm for autoimmune diseases.

Our Value Proposition

B

BIOLOGICS SIMILARS B E Ε R P ESS

Exclusively inclusive: **Biocon**

WE ARE DRIVEN BY THE QUEST TO DEVELOP AFFORDABLE BIOPHARMACEUTICALS FOR PATIENTS ACROSS THE WORLD. ENHANCING ACCESS TO OTHERWISE EXPENSIVE THERAPIES. WHEN WE STARTED OUR PHARMACEUTICAL JOURNEY, WE HAD A CHOICE TO DEVELOP LOW-COST GENERIC PHARMACEUTICALS OR COMPLEX CAPITAL-INTENSIVE PREMIUM PRODUCTS. WE CHOSE THE LATTER AND OPTED FOR BIOPHARMACEUTICALS THROUGH DISRUPTIVELY INNOVATIVE PROCESS ENGINEERING THAT COULD DELIVER AFFORDABLE PRICING AND MAKE A DIFFERENCE TO GLOBAL HEALTHCARE. A STRATEGY OF BEING PROFITABLY SMART

A STRATEGY OF BEING PROFITABLY SMART AND SOCIALLY GOOD.

